

FORM PTO 1449		ATTY. DOCKET NO. 966927.00007	APPLICATION NO. 10/026,931
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S) Mahler et al.	
		FILING DATE Dec. 27, 2001	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AB1	EP 1 219 300	06/16/06	Europe		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AC	1	Vrtala et al. Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p6, to Reduce Allergenic Activity and Preserve Immunogenicity. The Journal of Immunology, 2007, 179:1730-1739
AD	1	Mahler V et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy 2004: 34:115-122.
AE	1	Breiteneder et al. The gene coding for the major birch pollen allergen Bet v1, is highly homologous to a pea disease resistance response gene. The EMBO Journal 1989: Vol. 8, No. 7: 1935-1938
AF	1	Vrtala et al. Conversion of the Major Birch Pollen Allergen, Bet v1 into two nonanaphylactic T-Cell Epitope-containing Fragments. J. Clin. Invest. 1997 Vol. 99, No. 7, 1673-1681.
AG	1	Vrtala et al. T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet V1 induce blocking antibodies. The Journal of Immunology, 2000, 165:6653-6659.
AH	1	Vrtala et al. Strategies for Converting allergens into hypoallergenic vaccine candidates. Methods 32 (2004) 313-320.
AI	1	Flicker et al. Renaissance of the Blocking Antibody Concept in Type I Allergy. Int. Arch. Allergy Immunol. 2003:132:13-24.
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.